DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

Keratoacanthoma differential

Essential points for quick revision.

Synopsis

Recognise the rapidly growing crateriform keratoacanthoma pattern, understand why it cannot be safely distinguished from well-differentiated SCC clinically, and arrange urgent complete histological assessment.

  • A classic keratoacanthoma is a rapidly growing, symmetrical, dome-shaped nodule with a central keratin-filled crater on sun-exposed skin.
  • Growth over two to eight weeks is typical, but speed does not prove benignity; SCC can show the same crateriform pattern.
  • Manage a solitary suspected keratoacanthoma as SCC until complete architecture and depth have been assessed histologically.

Key red flags

Rapid growth, pain, lip or ear site, size over 2 cm, immune suppression, recurrence, fixation, neurological symptoms or a regional node increases SCC risk and requires urgent specialist assessment.

Rapid growth

Increase from papule to centimetre-scale tumour within several weeks is characteristic and itself triggers urgent assessment.

Investigation priorities

01
Complete excision histologyFirst step

Assess full crater architecture, invasive front, differentiation and margins while treating the lesion.

Management branches

Solitary crateriform lesionTreat as SCC until proven otherwise

A rapidly growing keratin-filled nodule is clinically compatible with keratoacanthoma.

  1. Document growth, site, size, neurological symptoms, immune state and nodes and make an urgent suspected-cancer referral.
  2. Arrange complete excision with adequate depth when feasible, preserving the specimen and orientation for histopathology.
Open full textbook Answer 2 questions
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom